Epilepsy biomarkers

Jerome Engel, Asla Pitkanen, Jeffrey A. Loeb, F. Edward Dudek, Edward H. Bertram, Andrew J. Cole, Solomon L. Moshe, Samuel Wiebe, Frances E. Jensen, Istvan Mody, Astrid Nehlig, Annamaria Vezzani

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

A biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue capable of generating spontaneous seizures; measure progression after the condition is established; and determine pharmacoresistance. Such biomarkers could be used to create animal models for more cost-effective screening of potential antiepileptogenic and antiseizure drugs and devices, and to reduce the cost of clinical trials by enriching the trial population, and acting as surrogate markers to shorten trial duration. The objectives of the biomarker subgroup for the London Workshop were to define approaches for identifying possible biomarkers for these purposes. Research to identify reliable biomarkers may also reveal underlying mechanisms that could serve as therapeutic targets for the development of new antiepileptogenic and antiseizure compounds. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalEpilepsia
Volume54
Issue numberSUPPL.4
DOIs
StatePublished - Aug 2013

Fingerprint

Epilepsy
Biomarkers
Seizures
Costs and Cost Analysis
Pathologic Processes
Animal Models
Clinical Trials
Education
Equipment and Supplies
Research
Pharmaceutical Preparations
Population

Keywords

  • Biomarkers
  • Epileptogenesis
  • Ictogenesis
  • Surrogate markers
  • Therapeutic intervention

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Engel, J., Pitkanen, A., Loeb, J. A., Dudek, F. E., Bertram, E. H., Cole, A. J., ... Vezzani, A. (2013). Epilepsy biomarkers. Epilepsia, 54(SUPPL.4), 61-69. https://doi.org/10.1111/epi.12299

Epilepsy biomarkers. / Engel, Jerome; Pitkanen, Asla; Loeb, Jeffrey A.; Dudek, F. Edward; Bertram, Edward H.; Cole, Andrew J.; Moshe, Solomon L.; Wiebe, Samuel; Jensen, Frances E.; Mody, Istvan; Nehlig, Astrid; Vezzani, Annamaria.

In: Epilepsia, Vol. 54, No. SUPPL.4, 08.2013, p. 61-69.

Research output: Contribution to journalArticle

Engel, J, Pitkanen, A, Loeb, JA, Dudek, FE, Bertram, EH, Cole, AJ, Moshe, SL, Wiebe, S, Jensen, FE, Mody, I, Nehlig, A & Vezzani, A 2013, 'Epilepsy biomarkers', Epilepsia, vol. 54, no. SUPPL.4, pp. 61-69. https://doi.org/10.1111/epi.12299
Engel J, Pitkanen A, Loeb JA, Dudek FE, Bertram EH, Cole AJ et al. Epilepsy biomarkers. Epilepsia. 2013 Aug;54(SUPPL.4):61-69. https://doi.org/10.1111/epi.12299
Engel, Jerome ; Pitkanen, Asla ; Loeb, Jeffrey A. ; Dudek, F. Edward ; Bertram, Edward H. ; Cole, Andrew J. ; Moshe, Solomon L. ; Wiebe, Samuel ; Jensen, Frances E. ; Mody, Istvan ; Nehlig, Astrid ; Vezzani, Annamaria. / Epilepsy biomarkers. In: Epilepsia. 2013 ; Vol. 54, No. SUPPL.4. pp. 61-69.
@article{b1dd8611a1874915a7da047d3f907d25,
title = "Epilepsy biomarkers",
abstract = "A biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue capable of generating spontaneous seizures; measure progression after the condition is established; and determine pharmacoresistance. Such biomarkers could be used to create animal models for more cost-effective screening of potential antiepileptogenic and antiseizure drugs and devices, and to reduce the cost of clinical trials by enriching the trial population, and acting as surrogate markers to shorten trial duration. The objectives of the biomarker subgroup for the London Workshop were to define approaches for identifying possible biomarkers for these purposes. Research to identify reliable biomarkers may also reveal underlying mechanisms that could serve as therapeutic targets for the development of new antiepileptogenic and antiseizure compounds. Wiley Periodicals, Inc.",
keywords = "Biomarkers, Epileptogenesis, Ictogenesis, Surrogate markers, Therapeutic intervention",
author = "Jerome Engel and Asla Pitkanen and Loeb, {Jeffrey A.} and Dudek, {F. Edward} and Bertram, {Edward H.} and Cole, {Andrew J.} and Moshe, {Solomon L.} and Samuel Wiebe and Jensen, {Frances E.} and Istvan Mody and Astrid Nehlig and Annamaria Vezzani",
year = "2013",
month = "8",
doi = "10.1111/epi.12299",
language = "English (US)",
volume = "54",
pages = "61--69",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL.4",

}

TY - JOUR

T1 - Epilepsy biomarkers

AU - Engel, Jerome

AU - Pitkanen, Asla

AU - Loeb, Jeffrey A.

AU - Dudek, F. Edward

AU - Bertram, Edward H.

AU - Cole, Andrew J.

AU - Moshe, Solomon L.

AU - Wiebe, Samuel

AU - Jensen, Frances E.

AU - Mody, Istvan

AU - Nehlig, Astrid

AU - Vezzani, Annamaria

PY - 2013/8

Y1 - 2013/8

N2 - A biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue capable of generating spontaneous seizures; measure progression after the condition is established; and determine pharmacoresistance. Such biomarkers could be used to create animal models for more cost-effective screening of potential antiepileptogenic and antiseizure drugs and devices, and to reduce the cost of clinical trials by enriching the trial population, and acting as surrogate markers to shorten trial duration. The objectives of the biomarker subgroup for the London Workshop were to define approaches for identifying possible biomarkers for these purposes. Research to identify reliable biomarkers may also reveal underlying mechanisms that could serve as therapeutic targets for the development of new antiepileptogenic and antiseizure compounds. Wiley Periodicals, Inc.

AB - A biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue capable of generating spontaneous seizures; measure progression after the condition is established; and determine pharmacoresistance. Such biomarkers could be used to create animal models for more cost-effective screening of potential antiepileptogenic and antiseizure drugs and devices, and to reduce the cost of clinical trials by enriching the trial population, and acting as surrogate markers to shorten trial duration. The objectives of the biomarker subgroup for the London Workshop were to define approaches for identifying possible biomarkers for these purposes. Research to identify reliable biomarkers may also reveal underlying mechanisms that could serve as therapeutic targets for the development of new antiepileptogenic and antiseizure compounds. Wiley Periodicals, Inc.

KW - Biomarkers

KW - Epileptogenesis

KW - Ictogenesis

KW - Surrogate markers

KW - Therapeutic intervention

UR - http://www.scopus.com/inward/record.url?scp=84888381473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888381473&partnerID=8YFLogxK

U2 - 10.1111/epi.12299

DO - 10.1111/epi.12299

M3 - Article

VL - 54

SP - 61

EP - 69

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL.4

ER -